Health
Moderna and Merck's personalized cancer vaccine succeeds in late-stage trial
The treatment, called intismeran autogene, uses a computer algorithm to design its custom mRNA genetic instructions.
The short version
- Moderna and Merck announced the late-stage trial success of their personalized cancer vaccine, intismeran autogene.
- The treatment utilizes a computer algorithm to determine individual genetic instructions, marking a potential first for approved medicines.
- The vaccine is currently awaiting regulatory review and potential approval.
Key facts
- Moderna and Merck co-developed a personalized cancer vaccine named intismeran autogene.[STAT]
- The companies announced that the vaccine successfully met its targets in a late-stage clinical trial.[STAT]
- A computer algorithm is used to determine the unique mRNA genetic instructions for each personalized vaccine.[STAT]
What remains uncertain
- The vaccine is still subject to regulatory review, and final approval is not yet guaranteed.[STAT]
Sources
- STAT+: The mystery of Moderna’s magic algorithmSTAT metered